By the Top Tier Newswire AI Desk · August 26, 2026 at 10:20 AM ET · reviewed against 26 wire stories
MODERNA INC (MRNA) is down -5.02% in the latest session. Our newswire has captured 26 stories on MRNA across 15 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Moderna Inc (MRNA) closed down 5.02% at $150.85 on Friday, marking a sharp reversal from its recent 147.1% surge over the last eight sessions. The decline followed a volatile intraday session that saw the stock open at $158.32 before falling to a low of $148.20. The move reflects a shift in sentiment after a period of optimism driven by the company’s Phase 3 melanoma trial success with Merck.
What Happened
The stock’s decline came after a sharp intraday pullback amid mixed market conditions and investor caution. Moderna shares had surged past $150 earlier in the week following a report that Wolfe highlighted a $9.2 billion opportunity for its cancer vaccine. However, the rally appears to have triggered profit-taking and a reassessment of the stock’s near-term potential. The session’s volume of 6.0 million shares was half the 3-month daily average, suggesting a lack of strong conviction in the move. Meanwhile, broader market attention turned to upcoming inflation data and Nvidia’s earnings, reducing focus on biotech names. Additionally, recent insider sales by top executives, including CEO Stephane Bancel, may have contributed to a sense of uncertainty among investors.
What The Data Shows
The stock’s recent performance has been marked by extreme volatility, with a 52-week range of $22.28 to $176.66. Despite the sharp rise, Moderna remains unprofitable, with a trailing twelve-month net margin of -141.4% and revenue declining 27.6% year-to-date. Short interest and unusual options activity suggest a mixed outlook, with $101.6 million in call premiums versus $23.2 million in puts over the last 36 hours. The stock also printed a fresh 52-week low on August 26, indicating some bearish pressure. Meanwhile, retail traders on r/wallstreetbets have expressed frustration over recent swings, though their commentary is not indicative of fundamental changes in the business.
What To Watch
Investors should monitor the broader market for signs of renewed risk appetite, particularly as key inflation data and Nvidia’s earnings report are due soon. Additionally, coverage breadth and analyst updates may provide further clarity on the stock’s trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MRNA · Aug 26 session (5-min) · -7.06% vs prior close · updated 8:51 PM ETAI sentiment, last 36h · averaged over 26 stories · 64/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
17d agoGlobeNewswireBULLISH 55General
mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More
Expanding oncology and rare disease pipelines, strategic partnerships, and advances in delivery technologies are expected to drive significant market...
18d agoSCMPBULLISH 73Product/PR
China rushes to develop Moderna-style cancer vaccines amid market frenzy
A group of Hong Kong-listed biotechnology companies have seen their stock prices surge in the wake of Moderna’s breakthrough cancer vaccine trial, as the Chinese companies push forward with similar vaccine programmes. The companies – from Jiangsu Hengrui Pharmaceuticals to Li Ka-shing-backed CK Life Sciences – already have a slew of cancer vaccines in development, which could have a large potential market given that nearly 2.6 million people die from cancer in China alone each year. “China is...
Treasury yields declined, as the benchmark 10-year Treasury note yield dropped by over 7 basis points to reach 4.63%.
18d agoStocktwits NewsBULLISH 73Product/PR
MRNA Stock Jumps 14% Past $150 As Wolfe Sees $9.2B Cancer-Vaccine Opportunity
The optimism around MRNA began last week after Moderna and partner Merck reported that their personalized cancer vaccine, intismeran, met key goals in a late-stage study for high-risk melanoma.
18d agoStocktwits NewsBULLISH 58General
KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook
According to a filing with the SEC, Kura President and CEO Troy Edward Wilson bought 100,000 shares of common stock on August 24 for about $1.24 million in total.
18d agoWSJ MarketsBULLISH 55General
Health Care Roundup: Market Talk
Gain insight on Moderna, Novo Nordisk and more in the latest Market Talks covering the Health Care sector.
18d agoSeeking AlphaBULLISH 73Product/PR
Moderna advances 14% amid post-trial repricing
Moderna (MRNA) surges on Phase 3 melanoma success with Merck—see key drivers, RSI, short interest, and analyst updates.
18d agoBarron'sBULLISH 63General
U.S. Markets Rose Tuesday; Moderna Climbed Highest
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →